TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06290141: A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Sponsor: Sanofi · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$661,152

Rescue Site Savings

+$440,768

Unlock Full NCT06290141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06290141 Rescue Dossier →